ABCL Stock Analysis: Abcellera Biologics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.678m USD | 12M Return: 190% | CA00288U1066 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 88.4M
Qual. Beats: 0
Rev. Trend: 47.6%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 5.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AbCellera Biologics Inc. (ABCL) is a Vancouver-based biotechnology company that discovers and develops antibody-based medicines targeting indications with unmet medical need, primarily in the United States. Its pipeline includes ABCL635, a non-hormonal therapy in Phase 2 trials for moderate-to-severe vasomotor symptoms, and ABCL575, a half-life extended monoclonal antibody in Phase 1 development for T-cell-mediated autoimmune conditions such as atopic dermatitis. The company operates a partnership-driven business model, with research collaborations and license agreements with Eli Lilly, AbbVie, Biogen, and other investors, suggesting a reliance on milestone payments, royalties, and licensing revenue typical of clinical-stage biotech firms. Founded in 2012 and listed on NASDAQ since December 2020, AbCellera is classified within the Health Care sector under the Biotechnology sub-industry.
- ABCL635 Phase 2 vasomotor symptom trial data readout approaches
- Partnership milestones with Eli Lilly AbbVie Biogen drive royalty revenue
- Cash burn rate and runway shape capital allocation and dilution risk
| Net Income: -164.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.12 > 0.02 and ΔFCF/TA -2.40 > 1.0 |
| NWC/Revenue: 946.1% < 20% (prev 2.05k%; Δ -1.11k% < -1%) |
| CFO/TA -0.12 > 3% & CFO -154.7m > Net Income -164.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (305.6m) vs 12m ago 2.36% < -2% |
| Gross Margin: 56.45% > 18% (prev -209.5%; Δ 265.9% > 0.5%) |
| Asset Turnover: 4.88% > 50% (prev 2.34%; Δ 2.54% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.48 (Total Current Assets 679.2m - Total Current Liabilities 53.2m) / Total Assets 1.31b |
| B: -0.10 (Retained Earnings -128.1m / Total Assets 1.31b) |
| C: -0.15 (EBIT TTM -201.6m / Avg Total Assets 1.35b) |
| D: 2.18 (Book Value of Equity 896.0m / Total Liabilities 411.6m) |
| Altman-Z'' = 4.11 = AA |
| DSRI: 0.31 (Receivables 95.4m/153.4m, Revenue 66.2m/32.9m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: -1.25 (AQ_t -0.21 / AQ_t-1 0.17) |
| SGI: 2.01 (Revenue 66.2m / 32.9m) |
| TATA: -0.01 (NI -164.7m - CFO -154.7m) / TA 1.31b) |
| Beneish M = -4.20 (Cap -4..+1) = AAA |
As of September 04, 2026, the stock is trading at USD 11.57 with a total of 3,284,230 shares traded. Over the past week, the price has changed by -6.69%, over one month by +98.46%, over three months by +102.27% and over the past year by +189.97%.
Current recommended Stop Loss: 10.50 (which is 9.2% or 1.3 ATR below the current price).
Abcellera Biologics has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy ABCL.
- StrongBuy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17.1 | 48.1% |
P/E Forward = 27.5482
P/S = 55.5832
P/B = 4.4791
Revenue TTM = 66.2m USD
EBIT TTM = -201.6m USD
EBITDA TTM = -160.3m USD
Long Term Debt = 129.9m USD (estimated: total debt 135.6m - short term 5.67m)
Short Term Debt = 5.67m USD (from shortTermDebt, last quarter)
Debt = 135.6m USD (from shortLongTermDebtTotal, last quarter) (leases 135.6m already included)
Net Debt = -404.5m USD (calculated: Debt 135.6m - CCE 540.1m)
Enterprise Value = 3.27b USD (3.68b + Debt 135.6m - CCE 540.1m)
Interest Coverage Ratio = unknown (Ebit TTM -201.6m / Interest Expense TTM 0.0)
EV/FCF = -21.62x (Enterprise Value 3.27b / FCF TTM -151.4m)
FCF Yield = -4.63% (FCF TTM -151.4m / Enterprise Value 3.27b)
FCF Margin = -228.8% (FCF TTM -151.4m / Revenue TTM 66.2m)
Net Margin = -248.8% (Net Income TTM -164.7m / Revenue TTM 66.2m)
Gross Margin = 56.45% ((Revenue TTM 66.2m - Cost of Revenue TTM 28.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev -4.09%)
Tobins Q-Ratio = 2.50 (Enterprise Value 3.27b / Total Assets 1.31b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 135.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -159.2m (EBIT -201.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.40 (Total Current Assets 679.2m / Total Current Liabilities 65.3m)
Debt / Equity = 0.15 (Debt 135.6m / totalStockholderEquity, last quarter 896.0m)
Debt / EBITDA = 2.52 (negative EBITDA) (Net Debt -404.5m / EBITDA -160.3m)
Debt / FCF = 2.67 (negative FCF - burning cash) (Net Debt -404.5m / FCF TTM -151.4m)
Total Stockholder Equity = 941.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.15% (Net Income -164.7m / Total Assets 1.31b)
RoE = -17.49% (Net Income TTM -164.7m / Total Stockholder Equity 941.3m)
RoCE = -18.82% (EBIT -201.6m / Capital Employed (Equity 941.3m + L.T.Debt 129.9m))
RoIC = -12.67% (negative operating profit) (NOPAT -159.2m / Invested Capital 1.26b)
WACC = 14.30% (E(3.68b)/V(3.81b) * Re(14.83%) + D(135.6m)/V(3.81b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 14.83% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 95.22 | Cagr: 1.93%
[DCF] Fair Price = unknown (Cash Flow -151.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.19 | # QB: 0
Revenue Correlation: 47.58 | Revenue CAGR: 23.16% | SUE: -0.28 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.17 | Chg30d=+0.97% | Revisions=+40% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.66 | Chg30d=-0.92% | Revisions=-25% | GrowthEPS=-33.9% | GrowthRev=-66.4%
EPS next Year (2027-12-31): EPS=-0.71 | Chg30d=+0.69% | Revisions=+0% | GrowthEPS=-9.0% | GrowthRev=-0.9%
[Analyst] Revisions Ratio: +17% (up=2, down=1)